Induction Chemotherapy Clinical Trial
Official title:
Envafolimab Plus Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma, a Prospective, Single Armed Phase II Trial.
Patients diagnosed with locally advanced nasopharyngeal carcinoma will be recruited in this study. All the patients will get 3 cycles of GP+ Envafolimab for the induction chemotherapy. After that, the patients will receive concurrent chemoradiotherapy. Radiotherapy will be given by IMRT, under the dose of GTVnx 68-70Gy/30-33f, 5d/w,6-7w, during which, every patient would receive 2 cycles of DDP+Envafolimab as concurrent chemotherapy. Then patients would receive Envafolimab every 3 weeks for maintenance treatment for a year, until disease progression or intolerance of treatment. . We aim to evaluate the three years progression free survival of these patients by the combination of Envafolimab with curative chemoradiotherapy.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04539600 -
Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer
|
Phase 2 | |
Completed |
NCT04473716 -
Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients
|
Phase 1 | |
Recruiting |
NCT06093438 -
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04446130 -
Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients
|
Phase 3 | |
Recruiting |
NCT02924909 -
Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04384627 -
Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy
|
Phase 3 | |
Recruiting |
NCT05114707 -
Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses
|
Phase 2 | |
Recruiting |
NCT04087967 -
Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients
|
Phase 3 | |
Recruiting |
NCT04083911 -
Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60
|
Phase 3 |